Product Pipeline and Funding
Global Health and Pandemic Preparedness
Supported almost exclusively by non-dilutive funding, Aldatu has received $16M from the National Institute of Allergy and Infectious Diseases [NIAID] to advance diagnostics using our PANDAA technology platform.
Product Pipeline and Funding
Global Health and Pandemic Prevention, Preparedness and Response
Supported almost exclusively by non-dilutive funding, Aldatu has received $16M from the National Institute of Allergy and Infectious Diseases [NIAID] to advance diagnostics using our PANDAA technology platform.
The first pan-lineage real-time PCR assay for the qualitative detection of Lassa virus (LASV) RNA.
- The only assay for universal pan-lineage detection of the Lassa virus – detects all lineages of LASV with equal sensitivity.
- Fast – delivers accurate results from RNA in 1 hour
- One of the most sensitive LASV molecular diagnostics available, with a limit of detection 10 copies / reaction.
Available as an RUO product: aldatubio.com/product/pandaa-lassa-virus
The first universal, pan-clade CCHFV diagnostic.
- The first CCHFV diagnostic that meets the WHO R&D blueprint target product profile
- The only assay that can detect all CCHFV clades, and with equal sensitivity.
- Fast – delivers accurate results from RNA in 1 hour
- A limit of detection 10 copies / reaction.
Ebola (pan-species)
$3M NIAID SBIR
One assay. Every known Ebolavirus species.
- Detects all known Ebolavirus species — Zaire, Bundibugyo, Sudan, Taï Forest, and Reston — in a single real-time RT-PCR reactio
- Fast – delivers accurate results from RNA in ~1 hour
- A limit of detection 10 copies / reaction.
Ebola and Marburg
$3M NIAID SBIR
Under development to detect all species of Ebolavirus and differentiation with Marburgvirus.
- Detect and differentiate Ebolavirus from Marburgvirus.
- Detect all six species of Ebolavirus with equal sensitivity.
Yellow fever
Under development to detect all genotypes of Yellow fever virus and differentiate from vaccine strains.
- A universal molecular diagnostic to detect all Yellow fever virus genotypes.
- Distinguishes infections caused by wild-type virus from adverse events arising from immunization with the Yellow fever live, attenuated vaccine.
HIV Drug Resistance Genotyping
ReFocus I
$1.5M NIAID SBIR
Detects six drug resistance mutations (DRMs) in >99% of HIV-infected patients failing first-line antiretroviral treatment (ART).
Genotypes 24 patients in <2 hours.
Available as RUO product: aldatubio.com/product/pandaa-qdx-hivdr-rti/
ReFocus II
$3M NIAID SBIR
$3M NIAID Commercialization
Detects eight DRMs in HIV-infected patients failing protease inhibitor second-line antiretroviral treatment (ART). Genotypes 20 patients in <2 hours.
ExPAND
$3.3M NIAID Contract
Detects low-level DRM variants at 1% for all HIV antiretroviral drug classes.
Research reported on this page was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health under SBIR award numbers R44AI118441, R44AI128974, R43AI145704, R44AI157650, and R44AI172551. The content is solely the responsibility of Aldatu Biosciences and does not necessarily represent the official views of the National Institutes of Health.
Type your paragraph here
ReFocus I
$1.5M NIAID SBIR
Detects six drug resistance mutations (DRMs) in >99% of HIV-infected patients failing first-line antiretroviral treatment (ART). Genotypes 24 patients in <20 hours.
Available as RUO product: aldatubio.com/product/pandaa-qdx-hivdr-rti/
ReFocus II
$3M NIAID SBIR
$3M NIAID Commercialization
Detects eight DRMs in HIV-infected patients failing protease inhibitor second-line antiretroviral treatment (ART). Genotypes 20 patients in <2 hours.
ExPAND
$3.3M NIAID Contract
|
Detects low-level DRM variants at 1% for all HIV antiretroviral drug classes. |
Pandemic Preparedness
Viral Hemorrhagic Fevers
The first pan-lineage real-time PCR assay for the qualitative detection of Lassa virus (LASV) RNA.
- The only assay for universal pan-lineage detection of the Lassa virus – detects all lineages of LASV with equal sensitivity.
- Fast – delivers accurate results from RNA in 1 hour
- One of the most sensitive LASV molecular diagnostics available, with a limit of detection 10 copies / reaction.
Available as an RUO product: aldatubio.com/product/pandaa-qdx-lasv
The first universal, pan-clade CCHFV diagnostic.
- The first CCHFV diagnostic that meets the WHO R&D blueprint target product profile
- The only assay that can detect all CCHFV clades, and with equal sensitivity.
- Fast – delivers accurate results from RNA in 1 hour
- A limit of detection 10 copies / reaction.
Ebola and Marburg
$3M NIAID SBIR
Under development to detect all species of Ebolavirus and differentiation with Marburgvirus.
- Detect and differentiate Ebolavirus from Marburgvirus.
- Detect all six species of Ebolavirus with equal sensitivity.
Yellow fever
Under development to detect all genotypes of Yellow fever virus and differentiate from vaccine strains.
- A universal molecular diagnostic to detect all Yellow fever virus genotypes.
- Distinguishes infections caused by wild-type virus from adverse events arising from immunization with the Yellow fever live, attenuated vaccine.